

LABORATORY REPORT

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108

EXAMPLE, REPORT W

F 12/05/1988 35 Y WX000003826

Referral Testing

Collected: 11/01/2024 13:39 Received: 11/01/2024 13:39

Test Name Result Flag Ref-Ranges Units <u>Site</u>

Lead, Industrial Exposure Panel, Adults

ARRL Lead. Industrial. Whole Blood <=4.9 ug/dL Н

INTERPRETIVE INFORMATION: Lead, Industrial Exposure Panel, Adults

Analysis performed by Inductively Coupled Plasma-Mass Spectrometry (ICP-MS).

Elevated results may be due to skin or collection-related contamination, including the use of a noncertified lead-free collection/transport tube. If contamination concerns exist due to elevated levels of blood lead, confirmation with a second specimen collected in a certified lead-free tube is recommended.

Reference interval and interpretive comments are based on the CDC's "Childhood Lead Poisoning Prevention: Recommended Actions Based on Blood Lead Level" and the "Adult Blood Lead Epidemiology and Surveillance: Reference Blood Lead Levels (BLLs) for Adults in the U.S." Thresholds and time intervals for retesting, medical evaluation, and response vary by state and regulatory body. Actions described by OSHA in 1978 and finalized in 1983 are shown below. Contact your State Department of Health and/or applicable regulatory agency for specific guidance on medical management recommendations.

Concentration	Comment	
5-19.9 ug/dL	Medical removal is recommended for pregnant women or those who are trying or may become pregnant. Adverse health effects are possible. Reduced lead exposure and increased blood lead monitoring are recommended.	
20-69.9 ug/dL	Adverse health effects are indicated. Medical removal from lead exposure is required by OSHA if blood lead level exceeds 50 ug/dL. Prompt medical evaluation is recommended.	
Greater than 69.9 ug/dL	Critical. Immediate medical evaluation is recommended. Consider chelation therapy when symptoms of lead toxicity are present.	

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

WX000003826 Printed D&T: 11/01/24 13:41

G701000002

Ordered By: KAJAL SITWALA, MD, PHD WX0000000002353

Kaial V. Sitwala, MD. PhD - Medical Director Form: MM RL1 PAGE 1 OF 3



LABORATORY REPORT

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108

EXAMPLE, REPORT W

WX0000003826 F 12/05/1988 35 Y

Referral Testing

Collected: 11/01/2024 13:39 Received: 11/01/2024 13:39

Test Name Result Flag Ref-Ranges Units <u>Site</u>

"Occupational Safety and Health Standards: Lead (1983). 29 CFR Part 1910.1025 App C"

Action required for workers with Elevated Lead Values OSHA, Occupational Exposure to Lead, 1978

No. of Tests	Lead	Action Required
1	Greater than or equal to 40.0 ug/dL	Notification of worker in writing; medical examination of worker and consultation.
3 (average)	Greater than or equal to 50.0 ug/dL	Removal of worker from job with potential lead exposure.
1	Greater than or equal to 60.0 ug/dL	Removal of worker from job with potential lead exposure.
2	Less than	Reinstatement of worker in
	40.0 ug/dL	<pre>job with potential lead exposure is based upon symptoms and medical evaluation.</pre>

OSHA requirements in effect since 1978 call for the measurement of whole blood lead and zinc protoporphyrins (ZPP) (NCCLS document C42-A, Nov. 1996) to evaluate the occupational exposure to lead. OSHA requires ZPP whole blood testing to be reported in units of ug/dL. For adults, conversion of ZPP units of ug/dL whole blood assumes a hematocrit of 45 percent. Conversion factor: umol/mol heme x 0.584 = ug/dL.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Zinc Protoporphyrin (ZPP), WholeBld Ratio

71

н 0-69

m

umolZPP/molHe ARRL

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

G701000002 WX000003826 Printed D&T: 11/01/24 13:41 Ordered By: KAJAL SITWALA, MD, PHD WX0000000002353

Kaial V. Sitwala, MD. PhD - Medical Director Form: MM RL1 PAGE 2 OF 3



LABORATORY REPORT

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108 **EXAMPLE, REPORT W**

WX0000003826 F 12/05/1988 35 Y

Referral Testing

Collected: 11/01/2024 13:39 Received: 11/01/2024 13:39

<u>Test Name</u> <u>Result</u> <u>Flag Ref-Ranges</u> <u>Units</u> <u>Site</u>

INTERPRETIVE INFORMATION: Zinc Protoporphyrin (ZPP) WholeBld

Ratio

This test was performed on the ProtoFluor Z system manufactured by Helena Laboratories. The result is not comparable to results obtained from extraction-based methods or from the AVIV ZPP system.

The test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Zinc Protoporphyrin, Blood 41 H 0-40 ug/dL ARRL

INTERPRETIVE INFORMATION: Zinc Protoporphyrin, Blood

For occupational exposure to lead, OSHA requires ZPP whole blood concentration to be reported in units of ug/dL. For adults, conversion of ZPP to units of ug/dL assumes a hematocrit of 45%. This test was performed on the ProtoFluor Z system manufactured by Helena Laboratories. The result is not comparable to results obtained from extraction-based methods or from the AVIV ZPP system.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Performed By: ARUP Laboratories
500 Chipeta Way

Salt Lake City, UT 84108 Laboratory Director: Jonathan R. Genzen, MD, PhD

CLIA Number: 46D0523979

Reported Date: 11/01/2024 13:41 PBINP

Performing Site:

ARRL: ARUP REFERENCE LAB 500 Chipeta Way Salt Lake City UT 841081221

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

G701000002 WX0000003826 Printed D&T: 11/01/24 13:41 Ordered By: KAJAL SITWALA, MD, PHD WX00000000002353

Kajal V. Sitwala, MD, PhD - Medical Director Form: MM RL1 PAGE 3 OF 3